неделя, 6 септември 2009 г.

What are the common side effects?

As with all prescription medication there is always the possibility of side effects. Some of the more common side effects of this treatment include nausea, hot flushing, restlessness, agitation or a general feeling of being unwell. These side effect, often mild in severity, should pass in the majority of patients within the first week or so of treatment.

Who should not take Acomplia?

Acomplia should not be used in patients with the following conditions:

  • Severe renal impairment
  • In patients with uncontrolled serious psychiatric illness such as a major depression.
  • Patients who had a cardiovascular event (myocardial infarction, stroke, etc.) less than 6 months ago
  • Patients who are breastfeeding
  • Patients who are pregnant

Acomplia should be used with caution in patients with the following conditions:

  • Moderate renal impairment
  • Aged over 75 years
  • Patients with epilepsy
  • Patients using potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone)
  • Rare hereditary problems of galactose intolerance

In clinical trials certain depressive disorders or mood changes were also reported. Depressive disorders were found in up to 10% patients taking Acomplia whereas suicidal thoughts were reported in 1% of patients. Acomplia is not recommended with the following conditions:

  • Patients undergoing treatment for major depressive illness and taking anti-depression medications for it.
  • Patients currently having or who previously had suicidal thoughts and depressive disorders. If the benefits of Acomplia are found to be greater than risks, you can take Acomplia after consulting with the doctor.
  • Patients with uncontrolled psychiatric illness excluding depression

Before you begin your Acomplia treatment always inform your guardians or relatives about the possible risks of taking Acomplia. Immediately stop taking Acomplia if you experience any signs of depression disorder.

Няма коментари:

Публикуване на коментар